- -

A Gene Signature Combining the Tissue Expression of Three Angiogenic Factors is a Prognostic Marker in Early-stage Non-small Cell Lung Cancer

RiuNet: Repositorio Institucional de la Universidad Politécnica de Valencia

Compartir/Enviar a

Citas

Estadísticas

  • Estadisticas de Uso

A Gene Signature Combining the Tissue Expression of Three Angiogenic Factors is a Prognostic Marker in Early-stage Non-small Cell Lung Cancer

Mostrar el registro sencillo del ítem

Ficheros en el ítem

[Cerrado]
Nombre: Jantus-Lewintre;Sirera ...
Tamaño: 358.1Kb
Formato: PDF
Descripción: Versión editorial
Solicitar una copia al autor
dc.contributor.author Sanmartín, Elena es_ES
dc.contributor.author Sirera Pérez, Rafael es_ES
dc.contributor.author Usó, Marta es_ES
dc.contributor.author Blasco, Ana es_ES
dc.contributor.author Gallach, Sandra es_ES
dc.contributor.author Figueroa, Santiago es_ES
dc.contributor.author Martínez, Nieves es_ES
dc.contributor.author Hernando, Cristina es_ES
dc.contributor.author Honguero, Antonio es_ES
dc.contributor.author Martorell, Miguel es_ES
dc.contributor.author Guijarro, Ricardo es_ES
dc.contributor.author Rosell, Rafael es_ES
dc.contributor.author Jantus-Lewintre, Eloisa es_ES
dc.contributor.author Camps, Carlos es_ES
dc.date.accessioned 2017-05-11T12:29:23Z
dc.date.available 2017-05-11T12:29:23Z
dc.date.issued 2014-02
dc.identifier.issn 1068-9265
dc.identifier.uri http://hdl.handle.net/10251/80997
dc.description.abstract [EN] Background. Angiogenesis and lymphangiogenesis are key mechanisms for tumor growth and dissemination. They are mainly regulated by the vascular endothelial growth factor (VEGF) family of ligands and receptors. The aim of this study was to analyze relative expression levels of angiogenic markers in resectable non-small cell lung cancer patients in order to asses a prognostic signature that could improve characterization of patients with worse clinical outcomes. Methods. RNA was obtained from tumor and normal lung specimens from 175 patients. Quantitative polymerase chain reaction was performed to analyze the relative expression of HIF1A, PlGF, VEGFA, VEGFA(165b), VEGFB, VEGFC, VEGFD, VEGFR1, VEGFR2, VEGFR3, NRP1 and NRP2. Results. Univariate analysis showed that tumor size and ECOG-PS are prognostic factors for time to progression (TTP) and overall survival (OS). This analysis in the case of angiogenic factors also revealed that PlGF, VEGFA, VEGFB and VEGFD distinguish patients with different outcomes. Taking into account the complex interplay between the different ligands of the VEGF family and to more precisely predict the outcome of the patients, we considered a new analysis combining several VEGF ligands. In order to find independent prognostic variables, we performed a multivariate Cox analysis, which showed that the subgroup of patients with higher relative expression of VEGFA plus lower VEGFB and VEGFD presented the poorest outcome for both TTP and OS. Conclusions. The relative expression of these three genes can be considered as an angiogenic gene signature whose applicability for the selection of candidates for targeted therapies needs to be further validated. es_ES
dc.description.sponsorship This study was partially supported by a grant from the Instituto de Salud Carlos III (FIS PI06/1041 and PS09/1149), Red Tematica de Investigacion Cooperativa en Cancer (RD06/0020/1024), and FEDER. en_EN
dc.language Inglés es_ES
dc.publisher Springer Verlag (Germany) es_ES
dc.relation.ispartof Annals of Surgical Oncology es_ES
dc.rights Reserva de todos los derechos es_ES
dc.subject Endothelial-growth-factor es_ES
dc.subject Inhibitory splice variant es_ES
dc.subject Lymph-node metastasis es_ES
dc.subject VEGF-C es_ES
dc.subject Breast cancer es_ES
dc.subject Colorectal cancer es_ES
dc.subject Carcinoma es_ES
dc.subject Tumor es_ES
dc.subject Receptors es_ES
dc.subject Lymphangiogenesis es_ES
dc.subject.classification MICROBIOLOGIA es_ES
dc.title A Gene Signature Combining the Tissue Expression of Three Angiogenic Factors is a Prognostic Marker in Early-stage Non-small Cell Lung Cancer es_ES
dc.type Artículo es_ES
dc.identifier.doi 10.1245/s10434-013-3330-x
dc.relation.projectID info:eu-repo/grantAgreement/ISCIII//PI06%2F1041/
dc.relation.projectID info:eu-repo/grantAgreement/ISCIII//PS09%2F1149/
dc.relation.projectID info:eu-repo/grantAgreement/MSC//RD06%2F0020%2F1024/ES/RED TEMÁTICA DE INVESTIGACIÓN COOPERATIVA DEL CANCER/
dc.rights.accessRights Cerrado es_ES
dc.contributor.affiliation Universitat Politècnica de València. Escuela Técnica Superior de Ingeniería Agronómica y del Medio Natural - Escola Tècnica Superior d'Enginyeria Agronòmica i del Medi Natural es_ES
dc.description.bibliographicCitation Sanmartín, E.; Sirera Pérez, R.; Usó, M.; Blasco, A.; Gallach, S.; Figueroa, S.; Martínez, N.... (2014). A Gene Signature Combining the Tissue Expression of Three Angiogenic Factors is a Prognostic Marker in Early-stage Non-small Cell Lung Cancer. Annals of Surgical Oncology. 21(2):612-620. https://doi.org/10.1245/s10434-013-3330-x es_ES
dc.description.accrualMethod S es_ES
dc.relation.publisherversion http://doi.org/10.1245/s10434-013-3330-x es_ES
dc.description.upvformatpinicio 612 es_ES
dc.description.upvformatpfin 620 es_ES
dc.type.version info:eu-repo/semantics/publishedVersion es_ES
dc.description.volume 21 es_ES
dc.description.issue 2 es_ES
dc.relation.senia 282057 es_ES
dc.identifier.eissn 1534-4681
dc.identifier.pmid 24145997
dc.contributor.funder Instituto de Salud Carlos III
dc.contributor.funder Red Temática de Investigación Cooperativa en Cáncer
dc.contributor.funder European Regional Development Fund
dc.contributor.funder Ministerio de Sanidad y Consumo es_ES
dc.description.references Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. es_ES
dc.description.references Spiro SG, Tanner NT, Silvestri GA, et al. Lung cancer: progress in diagnosis, staging and therapy. Respirology. 2010;15:44–50. es_ES
dc.description.references Youlden DR, Cramb SM, Baade PD. The international epidemiology of lung cancer: geographical distribution and secular trends. J Thorac Oncol. 2008;3:819–31. es_ES
dc.description.references Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23:1011–27. es_ES
dc.description.references Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 2000;60:203–12. es_ES
dc.description.references Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358:2039–49. es_ES
dc.description.references Dvorak HF. Angiogenesis: update, 2005. J Thromb Haemost. 2005;3:1835–42. es_ES
dc.description.references Mattern J, Koomagi R, Volm M. Coexpression of VEGF and bFGF in human epidermoid lung carcinoma is associated with increased vessel density. Anticancer Res. 1997;17:2249–52. es_ES
dc.description.references Bremnes RM, Camps C, Sirera R. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer. 2006;51:143–58. es_ES
dc.description.references Zhu CQ, Shih W, Ling CH, Tsao MS. Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol. 2006;59:790–800. es_ES
dc.description.references Zhan P, Wang J, Lv XJ, et al. Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol. 2009;4:1094–103. es_ES
dc.description.references Salgia R. Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer. Cancer. 2011;117:3889–99. es_ES
dc.description.references Skobe M, Hawighorst T, Jackson DG, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med. 2001;7:192–8. es_ES
dc.description.references Pepper MS, Tille JC, Nisato R, Skobe M. Lymphangiogenesis and tumor metastasis. Cell Tissue Res. 2003;314:167–77. es_ES
dc.description.references Yokoyama Y, Charnock-Jones DS, Licence D, et al. Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma. Br J Cancer. 2003;88:237–44. es_ES
dc.description.references Ko YH, Jung CK, Lee MA, et al. Clinical significance of vascular endothelial growth factors (VEGF)-C and -D in resected non-small cell lung cancer. Cancer Res Treat. 2008;40:133–40. es_ES
dc.description.references Maekawa S, Iwasaki A, Shirakusa T, et al. Correlation between lymph node metastasis and the expression of VEGF-C, VEGF-D and VEGFR-3 in T1 lung adenocarcinoma. Anticancer Res. 2007;27:3735–41. es_ES
dc.description.references Niki T, Iba S, Tokunou M, Yamada T, Matsuno Y, Hirohashi S. Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma. Clin Cancer Res. 2000;6:2431–9. es_ES
dc.description.references Feng Y, Wang W, Hu J, Ma J, Zhang Y, Zhang J. Expression of VEGF-C and VEGF-D as significant markers for assessment of lymphangiogenesis and lymph node metastasis in non-small cell lung cancer. Anat Rec (Hoboken). 2010;293:802–12. es_ES
dc.description.references Greene FL, Page DL, Fleming ID, et al. AJCC cancer staging manual. New York: Springer; 2002. es_ES
dc.description.references Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29:e45. es_ES
dc.description.references Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669–76. es_ES
dc.description.references Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–50. es_ES
dc.description.references Donnem T, Al Saad S, Al Shibli K, et al. Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer. Clin Cancer Res. 2007;13:6649–57. es_ES
dc.description.references Pajares MJ, Agorreta J, Larrayoz M, et al. Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung. J Clin Oncol. 2012;30:1129–36. es_ES
dc.description.references Carrillo de Santa PE, Arias FC, Caso PE, et al. Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer. Cancer. 2009;115:1701–12. es_ES
dc.description.references Bonnesen B, Pappot H, Holmstav J, Skov BG. Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: relation to prognosis. Lung Cancer. 2009;66:314–8. es_ES
dc.description.references Seto T, Higashiyama M, Funai H, et al. Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer. Lung Cancer. 2006;53:91–6. es_ES
dc.description.references Reinmuth N, Thomas M, Meister M, Schnabel PA, Kreuter M. Current data on predictive markers for anti-angiogenic therapy in thoracic tumours. Eur Respir J. 2010;36:915–24. es_ES
dc.description.references Jantus-Lewintre E, Sanmartin E, Sirera R, et al. Combined VEGF-A and VEGFR-2 concentrations in plasma: diagnostic and prognostic implications in patients with advanced NSCLC. Lung Cancer. 2011;74:326–31. es_ES
dc.description.references Dowlati A, Gray R, Sandler AB, Schiller JH, Johnson DH. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab—an Eastern Cooperative Oncology Group Study. Clin Cancer Res. 2008;14:1407–12. es_ES
dc.description.references Hanrahan EO, Ryan AJ, Mann H, et al. Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res. 2009;15:3600–9. es_ES
dc.description.references Bates DO, Cui TG, Doughty JM, et al. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res. 2002;62:4123–31. es_ES
dc.description.references Das K, Zhao Y, Sugiono M, Lau W, Tan PH, Cheng C. Differential expression of vascular endothelial growth factor165b in transitional cell carcinoma of the bladder. Urol Oncol. 2007;25:317–21. es_ES
dc.description.references Woolard J, Wang WY, Bevan HS, et al. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 2004;64:7822–35. es_ES
dc.description.references Manetti M, Guiducci S, Romano E, et al. Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis. Circ Res. 2011;109:e14-e26. es_ES
dc.description.references Salven P, Lymboussaki A, Heikkila P, et al. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol. 1998;153:103–8. es_ES
dc.description.references Nash AD, Baca M, Wright C, Scotney PD. The biology of vascular endothelial growth factor-B (VEGF-B). Pulm Pharmacol Ther. 2006;19:61–9. es_ES
dc.description.references Mylona E, Alexandrou P, Giannopoulou I, et al. The prognostic value of vascular endothelial growth factors (VEGFs)-A and -B and their receptor, VEGFR-1, in invasive breast carcinoma. Gynecol Oncol. 2007;104:557–63. es_ES
dc.description.references Wei SC, Tsao PN, Yu SC, et al. Placenta growth factor expression is correlated with survival of patients with colorectal cancer. Gut. 2005;54:666–72. es_ES
dc.description.references Chen CN, Hsieh FJ, Cheng YM, et al. The significance of placenta growth factor in angiogenesis and clinical outcome of human gastric cancer. Cancer Lett. 2004;213:73–82. es_ES
dc.description.references Matsumoto K, Suzuki K, Koike H, et al. Prognostic significance of plasma placental growth factor levels in renal cell cancer: an association with clinical characteristics and vascular endothelial growth factor levels. Anticancer Res. 2003;23:4953–8. es_ES
dc.description.references Parr C, Watkins G, Boulton M, Cai J, Jiang WG. Placenta growth factor is over-expressed and has prognostic value in human breast cancer. Eur J Cancer. 2005;41:2819–27. es_ES
dc.description.references Maae E, Olsen DA, Steffensen KD, et al. Prognostic impact of placenta growth factor and vascular endothelial growth factor A in patients with breast cancer. Breast Cancer Res Treat. 2012;133:257–65. es_ES
dc.description.references Ho MC, Chen CN, Lee H, et al. Placenta growth factor not vascular endothelial growth factor A or C can predict the early recurrence after radical resection of hepatocellular carcinoma. Cancer Lett. 2007;250:237–49. es_ES
dc.description.references Zhang L, Chen J, Ke Y, Mansel RE, Jiang WG. Expression of placenta growth factor (PlGF) in non-small cell lung cancer (NSCLC) and the clinical and prognostic significance. World J Surg Oncol. 2005;3:68. es_ES
dc.description.references Cheng SJ, Lee JJ, Kok SH, et al. Expression of placenta growth factor: an independent factor for prediction of progression and prognosis of oral cancer. Head Neck. 2010;32:1363–9. es_ES
dc.description.references Woo IS, Park MJ, Byun JH, et al. Expression of placental growth factor gene in lung cancer. Tumour Biol. 2004;25:1–6. es_ES
dc.description.references Neal JW. Histology matters: individualizing treatment in non-small cell lung cancer. Oncologist. 2010;15:3–5. es_ES
dc.description.references Wheatley-Price P, Blackhall F, Lee SM, et al. The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials. Ann Oncol. 2010;21:2023–8. es_ES
dc.description.references Langer CJ, Besse B, Gualberto A, Brambilla E, Soria JC. The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:5311–20. es_ES
dc.description.references George ML, Tutton MG, Janssen F, et al. VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression. Neoplasia. 2001;3:420–7. es_ES
dc.description.references Charoenrat P, Rhys-Evans P, Eccles SA. Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis. Cancer. 2001;92:556–68. es_ES
dc.description.references Saintigny P, Kambouchner M, Ly M, et al. Vascular endothelial growth factor-C and its receptor VEGFR-3 in non-small-cell lung cancer: concurrent expression in cancer cells from primary tumour and metastatic lymph node. Lung Cancer. 2007;58:205–13. es_ES
dc.description.references Bo C, Xiaopeng D, Chuanliang P, Xiaogang Z. Expression of vascular endothelial growth factors C and D correlates with lymphangiogenesis and lymph node metastasis in lung adenocarcinoma. Thorac Cardiovasc Surg. 2009;57:291–4. es_ES
dc.description.references Nakamura Y, Yasuoka H, Tsujimoto M, et al. Prognostic significance of vascular endothelial growth factor D in breast carcinoma with long-term follow-up. Clin Cancer Res. 2003;9:716–21. es_ES
dc.description.references White JD, Hewett PW, Kosuge D, et al. Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma. Cancer Res. 2002;62:1669–75. es_ES
dc.description.references Donnem T, Al Shibli K, Andersen S, Al Saad S, Busund LT, Bremnes RM. Combination of low vascular endothelial growth factor A (VEGF-A)/VEGF receptor 2 expression and high lymphocyte infiltration is a strong and independent favorable prognostic factor in patients with nonsmall cell lung cancer. Cancer. 2010;116:4318–25. es_ES
dc.description.references Sands M, Howell K, Costello CM, McLoughlin P. Placenta growth factor and vascular endothelial growth factor B expression in the hypoxic lung. Respir Res. 2011;12:17. es_ES
dc.description.references Moffat BA, Chen M, Kariaapper MS, et al. Inhibition of vascular endothelial growth factor (VEGF)-A causes a paradoxical increase in tumor blood flow and up-regulation of VEGF-D. Clin Cancer Res. 2006;12:1525–32. es_ES


Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem